ThIs site is for U.S. healthcare professionals only


An oral phosphate binder with familiar administration guidelines

The administration of AURYXIA® (ferric citrate) is similar to that of other phosphate binders, with familiar guidelines for your dialysis team to instruct patients on proper use.1-6

Patients taking doxycycline should take it at least one hour before AURYXIA is administered.
Patients taking ciprofloxacin should take it at least 2 hours before or after AURYXIA is administered.


AURYXIA_Charts_oral drugs-13

  • For oral medications where a reduction in bioavailability would have a clinically significant effect, consider separation of timing of administration with AURYXIA



Study Design

The safety and efficacy of AURYXIA was studied in a multicenter, randomized, open-label, Phase III trial of 441 hyperphosphatemia patients with chronic kidney disease on hemodialysis and peritoneal dialysis over 56 weeks.

The primary endpoint of the pivotal trial was change in serum phosphorus from baseline (Week 52) to Week 56 between AURYXIA and placebo in a 4-week efficacy assessment (Placebo-Controlled Period), which followed a 52-week safety assessment (Active Control Period). At the final Active Control Period visit, AURYXIA patients were re-randomized to either continue AURYXIA treatment or receive placebo as part of the Placebo-Controlled Period.

FormulationEach AURYXIA® (ferric citrate) tablet contains 210 mg of ferric iron, equivalent to 1 g of ferric citrate.